
Please try another search
Kringle Pharma, Inc. engages in the research and development, manufactures, and sells hepatocyte growth factor (HGF) protein pharmaceuticals for regenerative medicines. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Ibaraki, Japan.
Name | Age | Since | Title |
---|---|---|---|
Kohichiro Yoshino | 75 | 2018 | Independent Outside Director |
Masahiro Motokawa | 50 | 2018 | Audit & Supervisory Board Member |
Akihiro Tomoyasu | 54 | 2016 | Part Time Director |
Yosuke Yamaguchi | 45 | 2018 | Audit & Supervisory Board Member |
Masato Fukui | 48 | 2020 | Independent Outside Director |
Kiichi Adachi | 58 | 2005 | President, CEO & Chairman |
Yoshiyuki Kayano | 45 | 2023 | GM of Quality Assurance Department & Director |
Koichi Murakami | 65 | 2021 | Director of Business Administration Dept., Business Management Dept. Manager & Director |
Daichika Hayata | 50 | 2022 | GM of Pharmaceutical Development and Pharmaceutical Affairs Department & Director |
Naomi Doi | 67 | 2024 | External Auditor & Supervisory Board Member |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review